Overview

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the safety and efficacy of a new ophthalmic suspension (Brinz/Brim) in lowering intraocular pressure (IOP) relative to its individual active components in subjects with open-angle glaucoma and/or ocular hypertension.

Phase:

Phase 3

Details

Lead Sponsor:

Alcon Research

Treatments:

Brimonidine Tartrate
Brinzolamide
Ophthalmic Solutions